vs
Side-by-side financial comparison of PCB BANCORP (PCB) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
PCB BANCORP is the larger business by last-quarter revenue ($29.2M vs $18.6M, roughly 1.6× SCYNEXIS INC). On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 11.3%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 10.4%).
PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
PCB vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $29.2M | $18.6M |
| Net Profit | — | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 45.0% | 56.3% |
| Net Margin | — | 65.7% |
| Revenue YoY | 11.3% | 1808.5% |
| Net Profit YoY | — | 376.5% |
| EPS (diluted) | $0.65 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $29.2M | $18.6M | ||
| Q3 25 | $30.4M | $334.0K | ||
| Q2 25 | $29.3M | $1.4M | ||
| Q1 25 | $26.9M | $257.0K | ||
| Q4 24 | $26.2M | $977.0K | ||
| Q3 24 | $25.3M | $660.0K | ||
| Q2 24 | $24.2M | $736.0K | ||
| Q1 24 | $23.9M | $1.4M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | $11.4M | $-8.6M | ||
| Q2 25 | $9.1M | $-6.9M | ||
| Q1 25 | $7.7M | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $7.8M | $-2.8M | ||
| Q2 24 | $6.3M | $-14.5M | ||
| Q1 24 | $4.7M | $411.0K |
| Q4 25 | 45.0% | 56.3% | ||
| Q3 25 | 52.3% | -2516.5% | ||
| Q2 25 | 43.3% | -701.0% | ||
| Q1 25 | 40.2% | -3350.2% | ||
| Q4 24 | 39.3% | — | ||
| Q3 24 | 42.2% | -1563.6% | ||
| Q2 24 | 36.3% | -1255.0% | ||
| Q1 24 | 27.2% | -692.5% |
| Q4 25 | — | 65.7% | ||
| Q3 25 | 37.5% | -2572.2% | ||
| Q2 25 | 31.0% | -504.8% | ||
| Q1 25 | 28.8% | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 30.8% | -425.5% | ||
| Q2 24 | 25.9% | -1964.4% | ||
| Q1 24 | 19.6% | 29.9% |
| Q4 25 | $0.65 | $0.25 | ||
| Q3 25 | $0.78 | $-0.17 | ||
| Q2 25 | $0.62 | $-0.14 | ||
| Q1 25 | $0.53 | $-0.11 | ||
| Q4 24 | $0.46 | — | ||
| Q3 24 | $0.52 | $-0.06 | ||
| Q2 24 | $0.43 | $-0.30 | ||
| Q1 24 | $0.33 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $207.1M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $390.0M | $49.4M |
| Total Assets | $3.3B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $207.1M | $40.0M | ||
| Q3 25 | $369.5M | $37.9M | ||
| Q2 25 | $263.6M | $44.8M | ||
| Q1 25 | $214.3M | $40.6M | ||
| Q4 24 | $198.8M | $59.3M | ||
| Q3 24 | $193.1M | $68.8M | ||
| Q2 24 | $177.6M | $73.0M | ||
| Q1 24 | $239.8M | $80.2M |
| Q4 25 | $390.0M | $49.4M | ||
| Q3 25 | $384.5M | $36.4M | ||
| Q2 25 | $376.5M | $44.5M | ||
| Q1 25 | $370.9M | $50.5M | ||
| Q4 24 | $363.8M | $55.1M | ||
| Q3 24 | $362.3M | $58.5M | ||
| Q2 24 | $353.5M | $60.4M | ||
| Q1 24 | $350.0M | $74.1M |
| Q4 25 | $3.3B | $59.0M | ||
| Q3 25 | $3.4B | $51.1M | ||
| Q2 25 | $3.3B | $60.7M | ||
| Q1 25 | $3.2B | $67.9M | ||
| Q4 24 | $3.1B | $90.6M | ||
| Q3 24 | $2.9B | $99.0M | ||
| Q2 24 | $2.9B | $107.8M | ||
| Q1 24 | $2.9B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.6M | $18.4M |
| Free Cash FlowOCF − Capex | $24.4M | — |
| FCF MarginFCF / Revenue | 83.6% | — |
| Capex IntensityCapex / Revenue | 7.5% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $46.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.6M | $18.4M | ||
| Q3 25 | $16.4M | $-8.7M | ||
| Q2 25 | $4.9M | $-7.5M | ||
| Q1 25 | $2.3M | $-7.5M | ||
| Q4 24 | $39.0M | $-24.0M | ||
| Q3 24 | $11.9M | $765.0K | ||
| Q2 24 | $14.6M | $-10.9M | ||
| Q1 24 | $8.2M | $-4.0M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $16.2M | — | ||
| Q2 25 | $3.8M | — | ||
| Q1 25 | $1.6M | — | ||
| Q4 24 | $34.9M | — | ||
| Q3 24 | $11.9M | — | ||
| Q2 24 | $12.8M | — | ||
| Q1 24 | $6.0M | — |
| Q4 25 | 83.6% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 13.1% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 133.2% | — | ||
| Q3 24 | 46.8% | — | ||
| Q2 24 | 53.1% | — | ||
| Q1 24 | 25.2% | — |
| Q4 25 | 7.5% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 15.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 7.3% | — | ||
| Q1 24 | 9.3% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 2.33× | — | ||
| Q1 24 | 1.76× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCB
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
